



transformed by **yes**

Another future made better by Ionis innovation.

Ionis is the leading innovator in RNA-targeted therapeutics working to develop breakthrough medicines for sick people who depend on us.

Ionis is a sustainably profitable, multi-product company with a pipeline of more than 40 first-in-class and/or best-in-class medicines. We have created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective or ever existed. We create novel therapies that address undruggable targets in neurological disease, cardiovascular disease, rare diseases, infectious diseases and cancer.

Quick facts:

Founded in 1989:
Publicly traded
company since 1991
(NASDAQ: IONS)

Headquartered
in Carlsbad, CA

Approximately
500 employees

We pioneered the development of
antisense technology, a novel, more
efficient drug discovery platform

Our leadership team:

- + **Stanley T. Crooke, M.D., Ph.D.** Chairman of the Board & Chief Executive Officer
- + **Brett P. Monia, Ph.D.** Chief Operating Officer and Senior Vice President, Translational Medicine
- + **Elizabeth L. Hougen** Senior Vice President, Finance and Chief Financial Officer
- + **Patrick R. O’Neil, Esq.** Senior Vice President, Legal and General Counsel
- + **Damien McDevitt, Ph.D.** Chief Business Officer
- + **C. Frank Bennett, Ph.D.** Senior Vice President, Research
- + **Richard S. Geary, Ph.D.** Senior Vice President, Development

Our medicines:



Commercial and development partner: Biogen



Commercial affiliate: Akcea



Commercial affiliate: Akcea

